StockNews.com began coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Free Report) in a report released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock. Infinity Pharmaceuticals Price Performance Shares of NASDAQ:INFI opened at $0.10 on Friday. The business’s 50 day moving average price is $0.17 and its 200-day moving […]
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that.
NFI chief executive Paul Soubry says the company expects some temporary inefficiencies as it looks to increase production, but it sees a path for significant margin growth in 2024 and 2025